Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
ConditionAge-Related Macular Degeneration
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorUniversity of Wisconsin, Madison
About this trial
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Eligibility criteria
Qualifiers
Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
Disqualifiers
Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
Unable to acquire adequate quality images, as evaluated by the Central Reading Center
Severe vision loss requiring urgent surgery
Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
Trial design
Treatments tested in this trial
- Retinal Imaging
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov